A Study of Neoadjuvant Nivolumab + Abemaciclib or Palbociclib + Anastrozole in Post-Menopausal Women and Men With Primary Breast Cancer
Conditions: Breast Cancer; Cancer Interventions: Biological: Nivolumab; Drug: Abemaciclib; Drug: Anastrozole; Drug: Palbociclib Sponsor: Bristol-Myers Squibb Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Arimidex | Breast Cancer | Cancer | Cancer & Oncology | Men | Menopause | Neoadjuvant Therapy | Research | Study | Women